Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Gentamicin in RDEB with Nonsense Mutations
NCT03392909Phase 2Unknown
- Sponsor
- University of Southern California
- Start
- Jul 2018
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 2, open-label trial of gentamicin in Recessive Dystrophic Epidermolysis Bullosa (RDEB) (2 cohorts), sponsored by University of Southern California. Primary endpoints: Full-length type VII collagen expression at 6 months, Generation of anchoring fibrils at 6 months and 1 more. Status: unknown.
02
Drugs
gentamicin
03
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Beyond the preview
Go deeper on NCT03392909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03392909.